The contraceptive drugs market size was valued at USD 19.55 billion in 2024 and is expected to reach USD 36.42 billion by 2032, growing at a CAGR of 8.14% over the forecast period of 2025-2032.
The global contraceptive drugs market is growing steadily due to high awareness about family planning, increasing need for various birth control methods, and government endorsement in developed and emerging regions. The increasing number of women in the reproductive age group and the availability of over-the-counter contraceptives also contribute to a supportive market. Further changes in the market are coming from innovations in non-hormonal and long-acting contraceptives that are transforming the market and creating a more diverse and inclusive product portfolio.
The U.S. contraceptive drugs market size was valued at USD 7.01 billion in 2024 and is expected to reach USD 12.74 billion by 2032, growing at a CAGR of 7.81% over the forecast period of 2025-2032. The North American contraceptive drugs market is dominated by the U.S., which has a developed healthcare system, heightened consciousness about reproductive health, and extensive access to varied methods of contraception. Coupled with such strong government support for family planning and the presence of major pharmaceutical companies in the country.
In FY 2024, the U.S. Congress appropriated USD 607.5 million for international family planning and reproductive health, enabling 47.6 million women and couples around the world to avoid 17.1 million unintended pregnancies and 34,000 women to die.
Market Dynamics:
Drivers
More healthcare providers, universities, and public health organizations have been working to promote awareness of reproductive health and family planning. More and more educational campaigns and sex education programs are included in school curricula and community outreach in urban areas. An increase in awareness regarding reproductive health makes people, such as adolescents and youth, go for confirmed methods of birth control, which in turn amplifies the market of contraceptive drugs, including oral pills, patches, injectables, among others.
The KFF Women’s Health Survey found that 82% of women of reproductive age used any type of contraception, and one in four found contraceptive information on social media, with a significant effect on method choices, particularly in the 18–25-year-old population.
Internationally in 2022, a total of 874 million women (77.5%) of reproductive age were adopting a modern contraceptive method (up from 67% in 1990), showing long-term improving trends in attention and availability.
The national governments, as well as the international organisations (WHO and UNFPA), are still pushing family planning as an important element of public health. They aim to broaden access to contraceptive drugs to a larger portion of the population, particularly in the developing world, via subsidies, free distribution programs, and the integration of contraceptive services into public health clinics. These initiatives are helping to drive substantial increases in the uptake of contraceptive drugs across populations by mitigating barriers related to cost and availability.
The Bill & Melinda Gates Foundation is scaling up its investments in contraceptive research and distribution, with a focus on new methods and infrastructure delivery in low- and middle-income countries. The initiatives include a local drug shop and digitally-enabled health solutions access
Restraint
The large incidence of negative side effects associated with hormonal formulations is among the primary restraints preventing the widespread use of contraceptive pills. Several common oral contraceptives, as well as some injectable methods, depend on artificial hormones, including estrogen and progestin, which can create a variety of side effects, including nausea, weight gain, emotional changes, breast tenderness, low sex drive, and an unsteady menstrual cycle. Even more infrequent, but serious risks consist of blood clots, stroke, and cardiovascular troubles, specifically in women who smoke or who are 35 years of age or older.
Such health concerns can discourage new users from initiating contraception, and contribute to high discontinuation rates among current users. Another big factor, especially among young women and in areas with limited access to medical guidance, is fear of longer-term effects on fertility or hormone balance. Thus, safety concerns related to contraceptive medications are a major obstacle for the continued growth of the market, fuelling the need for safer, non-hormonal alternatives.
By Product
The oral contraceptive pills segment dominated the contraceptive drugs market share with an 82.40%, due to its long-standing popularity, ease of use, and high efficacy with perfect use in 2024. Often, a first choice when women are starting on contraception, these pills are available both over the counter and by prescription in many regions. Daily oral administration along with extensive hormonal formulations, newly available through regional markets, has made this segment the most secure and accessible option in developed and developing nations alike.
The Injectable Contraceptives segment is expected to register the fastest growth during the forecast period, owing to their long-acting property, allowing for reduced daily adherence. This type of contraceptive is very popular in less economically developed countries, as, in most cases, there is no possibility of timely access to the services of a medical specialist. Moreover, increased government and NGO advocacy for long-acting reversible contraceptives (such as injectables) has resulted in broader public health initiatives to promote the use of such contraceptives, particularly in the underserved areas.
By Age Group
The age group in the 2024 contraceptive drugs market was dominated by the 15–24 years segment with a 68.10% market share. This is due to the increased awareness and education in adolescents and young adults about sexual health. This group frequently first starts to use contraception in these formative years, particularly in cities where healthcare and family planning services are available. Also, educational campaigns initiated by educational institutions, governments, and non-profits aimed at preventing teenage pregnancies and promoting safe sex have considerably increased the use of contraceptive drugs among this demographic segment.
The 25–34 years segment is likely to experience the fastest growth during the forecast period, owing to being career-oriented and delaying childbirth while being on appropriate birth control. This age range usually correlates with more stable income levels and access to better healthcare, allowing for educated family planning choices. Additionally, this group favors long-acting methods and is likely to have more significant engagement with healthcare professionals, resulting in higher per capita prescriptions and a wider consumption of a range of contraceptive medications.
By End User
The homecare segment contraceptive drugs market with a 74.16% market share in 2024, owing to the convenience, privacy, and easy accessibility of these devices to the people using the market. Most (if not all) contraceptive preparations, especially oral pills and topical forms, are self-administered and can be used at home with no supervision from a medical professional. At-home care is the direction young folks and career women are going when seeking a discreet, convenient solution.
Demand for Injectable contraceptives, implants, and specialty contraceptive counselling services is expected to propel the fastest growth in the hospitals segment in the forecast years. These approaches usually need to be administered or monitored by health care workers, making hospitals an undeniable contact point for users of long-lasting or more permanent birth control techniques. Moreover, government-supported family planning programs and increased focus on postpartum contraception in clinical settings are increasingly making hospitals important sites of contraceptive care.
North America dominates the contraceptive drugs market with 41.06% market share in 2024 due to the most developed healthcare systems around the globe, full insurance coverage, and strong public awareness about reproductive health and family planning. Additionally, mature distribution channels and the presence of large pharmaceutical companies aggressively marketing a wide array of contraceptives, such as oral pills, injectable patches, are favorable factors for this region. What contributes to the large prevalence of use, especially in the U.S. and Canada, is the support of federal programs, the existence of some contraceptive drugs available over the counter, and sex-ed classes that teach positive information about sexual health.
Asia Pacific is the fastest-growing region in the contraceptive drugs market with an 8.71% CAGR due to a large population base, growing attention towards reproductive rights, and enhanced access to health care services. Countries such as India, China, and Indonesia are pouring resources into public health campaigns encouraging family planning, with the help of international organizations. Increasing female workforce participation, along with rapid urbanization, is fueling sales of contraceptive drugs in the region, while the expansion of pharmaceutical distribution in rural areas is expected to boost contraceptive drug sales further.
The contraceptive drugs market in Europe is expanding significantly due to the growing concern regarding family planning, unintentional pregnancies, and sexually transmitted infections across countries such as the UK, Germany and France is anticipated to stimulate the demand for effective birth control. Availability and adoption are being bolstered by major investments in modern contraceptive solutions, including hormonal pills, patches, and long-acting reversible contraceptives. In addition, supportive policies are further boosting market growth. At the same time, some governments in Europe, such as Luxembourg, have started programs to offer free or reimbursed contraception, making it more accessible for larger parts of the population. The huge growth of the contraceptive drugs market in Europe will be due to continuous research, approval of more products, and enhancement of reproductive health education.
The contraceptive drugs market in Latin America is projected to grow at a moderate CAGR due to the growing public health initiatives, gradual improvement in healthcare infrastructure, and rising awareness regarding reproductive health. Well-established programs aimed at lowering unwanted pregnancies have encouraged the use of contraceptive approaches. The cultural acceptance and constant efforts in educating the population for oral contraceptives and injectables have also led to more extensive consumption of such methods across the region.
The Middle East & Africa (MEA) region is growing moderately, although there is significant country variation due to differences in socio-cultural norms and access to healthcare. After concerted efforts from international organisations and local governments to promote women’s health and family planning services, the use of contraceptive drugs is slowly on the rise. Though hurdles exist as to accessibility in rural markets and conservatism, awareness campaigns and policy assistance are slowly driving the contraceptive drugs market growth.
Key Market Players
Bayer AG, Pfizer Inc., Merck & Co., Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan), Agile Therapeutics, Organon Group, Afaxys, Inc., Perrigo (HRA Pharma), and other players
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 19.55 Billion |
| Market Size by 2032 | USD 36.42 Billion |
| CAGR | CAGR of 8.14% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) • By Age Group (15–24 years, 25–34 years, 35–44 years, Above 44 years) • By End User (Homecare, Hospitals, Clinics) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Bayer AG, Pfizer Inc., Merck & Co., Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan), Agile Therapeutics, Organon Group, Afaxys, Inc., Perrigo (HRA Pharma), and other players |
Ans: The Contraceptives Drugs Market is expected to grow at a CAGR of 8.14% from 2025 to 2032.
Ans: The Contraceptives Drugs Market was USD 19.55 billion in 2024 and is expected to reach USD 36.42 billion by 2032.
Ans: Government and NGO support for birth control programs is propelling the market growth.
Ans: The “Oral Contraceptive Pills” segment dominated the Contraceptives Drugs Market.
Ans: North America dominated the Contraceptives Drugs Market in 2024.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2024)
5.2 Prescription Trends (2024), by Region
5.3 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket), 2024
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Contraceptives Drugs Market Segmentation By Product
7.1 Chapter Overview
7.2 Oral Contraceptive Pills
7.2.1 Oral Contraceptive Pills Market Trends Analysis (2021-2032)
7.2.2 Oral Contraceptive Pills Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Injectable Contraceptives
7.3.1 Injectable Contraceptives Market Trends Analysis (2021-2032)
7.3.2 Injectable Contraceptives Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Topical Contraceptives
7.4.1 Topical Contraceptives Market Trends Analysis (2021-2032)
7.4.2 Topical Contraceptives Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Contraceptives Drugs Market Segmentation By Age Group
8.1 Chapter Overview
8.2 15–24 years
8.2.1 15–24 years Market Trend Analysis (2021-2032)
8.2.2 15–24 years Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 25–34 years
8.3.1 25–34 years Market Trends Analysis (2021-2032)
8.3.2 25–34 years Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 35–44 years
8.4.1 35–44 years Market Trends Analysis (2021-2032)
8.4.2 35–44 years Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Above 44 years
8.5.1 Above 44 years Market Trends Analysis (2021-2032)
8.5.2 Above 44 years Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Contraceptives Drugs Market Segmentation By End User
9.1 Chapter Overview
9.2 Homecare
9.2.1 Homecare Market Trends Analysis (2021-2032)
9.2.2 Homecare Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Hospitals
9.3.1 Hospitals Market Trends Analysis (2021-2032)
9.3.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Clinics
9.4.1 Clinics Market Trends Analysis (2021-2032)
9.4.2 Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Contraceptives Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.4 North America Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.2.5 North America Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.6.2 USA Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.2.6.3 USA Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.7.2 Canada Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.2.7.3 Canada Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.8.2 Mexico Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.2.8.3 Mexico Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Contraceptives Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.4 Europe Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.5 Europe Contraceptives Drugs Market Estimates and Forecasts, By End User(2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.1.6.2 Germany Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.1.6.3 Germany Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.7.2 France Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.7.3 France Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.8.2 UK Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.8.3 UK Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.9.2 Italy Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.9.3 Italy Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.10.2 Spain Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.10.3 Spain Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Contraceptives Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.12.3 Poland Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.12.3 Poland Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.13.2 Turkey Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.13.3 Turkey Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Contraceptives Drugs Market Estimates and Forecasts, By End User(2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Contraceptives Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.6.2 China Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.6.3 China Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.7.2 India Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.7.3 India Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.8.2 Japan Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.8.3 Japan Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.9.2 South Korea Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.9.3 South Korea Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.10.2 Singapore Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.10.3 Singapore Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.11.2 Australia Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.11.3 Australia Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Contraceptives Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.6.2 UAE Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.5.6.3 UAE Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.8.2 Qatar Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.5.8.3 Qatar Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.9 2 South Africa Contraceptives Drugs Market Estimates and Forecasts By Age Group (2021-2032) (USD Billion)
10.5.9 3 South Africa Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Contraceptives Drugs Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.4 Latin America Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.6.5 Latin America Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.6.2 Brazil Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.6.6.3 Brazil Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.7.2 Argentina Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.6.7.3 Argentina Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Contraceptives Drugs Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Contraceptives Drugs Market Estimates and Forecasts, By Age Group (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Contraceptives Drugs Market Estimates and Forecasts, By End User (2021-2032) (USD Billion)
12. Company Profiles
12.1 Bayer AG
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Pfizer Inc.
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Merck & Co., Inc.
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 AbbVie Inc.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Teva Pharmaceutical Industries Ltd.
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Viatris Inc. (Mylan)
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Agile Therapeutics
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Organon Group
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Afaxys, Inc.
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Perrigo/HRA Pharma
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
By Age Group
By End User
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/sample-request/7472
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: https://www.snsinsider.com/sample-request/7472
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report: